bendamustine + temozolomide

Bendamustine + temozolomide is an investigational chemotherapy combination that pairs two distinct DNA-alkylating agents to enhance cytotoxicity against malignant cells, particularly in primary and secondary central nervous system lymphomas and gliomas. Bendamustine is a bifunctional mechlorethamine-derived alkylating agent with additional benzimidazole antimetabolite features, producing intra- and inter-strand DNA crosslinks that disrupt replication and induce apoptosis and other forms of cell death.[2][5][13] Temozolomide is an oral imidazotetrazine prodrug that spontaneously converts to MTIC at physiological pH and generates a reactive methyl diazonium species, which predominantly methylates guanine residues (N7 and O6) and adenine (O3), triggering mismatch repair–mediated DNA strand breaks and tumor cell apoptosis, especially in MGMT-deficient tumors.[8][10][11][14] The rationale for combining bendamustine with temozolomide is to exploit complementary alkylation and DNA-damage profiles to overcome resistance and improve activity in heavily pretreated or refractory CNS malignancies, albeit with significant additive myelosuppression as a key dose-limiting toxicity.[10][13]